IBS Clinical Trial
Official title:
The Effect of Two Probiotic Products on the Intestinal Barrier Function in Patients With Irritable Bowel Syndrome
This study will investigate the effects of supplementation with two different probiotic products (Lactobacillus reuteri strains) on the intestinal barrier function, gut health and stress symptoms in diarrhoea-predominant irritable bowel syndrome (IBS-D) patients.
After having given their written informed consent, subjects will complete screening procedures to evaluate their eligibility for the study (visit 1). Study participants will undergo two baseline visits (visits 2 and 3, 3 weeks apart) to account for individual variations, and will then be randomly assigned to 6-week intake of one of two Lactobacillus reuteri strains, or placebo in a ratio of 1:1:1 (stratified by sex). Participants will attend a study visit three weeks into the intervention (visit 4) and at the end of the intervention (visit 5, week 6). The intestinal permeability will be assessed using a standardized multi-sugar test at visit 2, visit 3, visit 4, and at end of intervention (visit 5). Blood, saliva and faecal samples will be collected at visit 2-5. In addition, gastrointestinal symptoms will be recorded at those visits (using Gastrointestinal symptom rating scale-IBS, GSRS-IBS; IBS severity scoring system, IBS- SSS). Quality of life using the 5Q-5D-5L and Hospital Anxiety and Depression Scale (HADS) scores will also be recorded at those visits. In addition, at visit 3 and visit 5, the IBS-Quality of life (IBS-QoL) and the Perceived Stress Scale (PSS) will be completed. In a daily diary, participants will record stool frequency and consistency from visit 2 until end-of-study visit 5. Dietary habits of the patients will be assessed via a food frequency questionnaire (FFQ) and a 3-day food diary before the intervention (between visit 2 and 3). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04677881 -
Health Effects of Different Types of Bread
|
N/A | |
| Completed |
NCT02293343 -
24 Hrs Histamine Profile in Healthy Persons and Patients With Food Intolerance
|
N/A | |
| Completed |
NCT01717404 -
Effects of Mexiletine on Colonic Transit in a Patient With Irritable Bowel Syndrome - Constipation (IBS-C)
|
Phase 1 | |
| Withdrawn |
NCT02313207 -
Confocal Laser Endomicroscopy in IBS Patients
|
N/A | |
| Completed |
NCT02937506 -
Patient Satisfaction With Propofol for Out Patient Colonoscopy
|
Phase 4 | |
| Terminated |
NCT05579444 -
Systems Biology of Gastrointestinal and Related Diseases
|
||
| Completed |
NCT02419963 -
Analyzing IBS to Identify Biomarkers and Microbiome Signatures
|
N/A | |
| Recruiting |
NCT06389851 -
Effects of Tomato Consumption on Steatosis, Intestinal Function and Glucose and Lipid Metabolism in Subjects With NAFLD
|
N/A | |
| Recruiting |
NCT05815602 -
Ebastine Versus Mebeverine in IBS Patients
|
Phase 3 | |
| Completed |
NCT03482765 -
A Study of Probiotics in IBS Subjects
|
N/A | |
| Recruiting |
NCT06275906 -
Influence of a Mediterranean Diet Combined With a Physical Activity Intervention, on NAFLD and Inflammation Parameters.
|
N/A | |
| Not yet recruiting |
NCT05737277 -
Gabapral in Pediatric IBS
|
N/A | |
| Active, not recruiting |
NCT05718505 -
Comparison of the Atmo Motility Gas Capsule System to the Reference Standard
|
N/A | |
| Recruiting |
NCT06072287 -
The Living With a Long-Term Condition Study
|
||
| Completed |
NCT04953728 -
Optimization of Transcutaneous Electrical Acustimulation (TEA) Modalities for Treatment of IBS-C
|
N/A | |
| Completed |
NCT02681666 -
Mindfulness-Based Eating in Patients With Irritable Bowel Syndrome
|
N/A | |
| Completed |
NCT02981888 -
Fecal Metabolome and the Intestinal Microbiota in Irritable Bowel Syndrome
|
||
| Completed |
NCT01667627 -
Probiotic in Irritable Bowel Syndrome (IBS) Patients With Diarrhea
|
Phase 4 | |
| Recruiting |
NCT01779765 -
The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome (IBS)
|
Phase 4 | |
| Completed |
NCT02009618 -
The Effects of Rifaximin Therapy in Irritable Bowel Syndrome
|
N/A |